Available April 1: The only FDA-approved vaccine that helps prevent all 5 leading types of meningococcal meningitis

Source: www.penbraya.com

PENBRAYA is available for order beginning April 1, 2024.  PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.  PENBRAYA is approved for use in individuals 10 through 25 years of age. 

PENBRAYA combines 2 vaccines that have nearly 10 years of experience to help protect against all 5 leading types of meningitis—A, B, C, W, and Y. Patients can now get the broadest protection against all 5 leading types of meningococcal meningitis with the fewest shots.

Click here for more information.

If you are interested in ordering, please contact Tina Clark, Contract Administrator, at tina@prn-gpo.com or (888)776-2360.

Save 6% now on MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine

Sanofi is offering a 6% sales promotion on all MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine orders placed between February 5, 2024 and March 31, 2024. You can schedule MenQuadfi® orders to ship immediately or future ship through October 31, 2024 on VaccineShop.com or VaxServe.com. Scheduling orders now can help you manage your inventory throughout the back-to-school season. 

If you have any additional questions, please feel free to contact a Sanofi representative or call Sanofi’s customer service at 1-800-822-2463.

Empower Your COVID-19 Fight: Essential Vaccine Insights

As we navigate a world where COVID-19 is one of many health concerns, your commitment to patient care remains invaluable. Your expertise and counsel continue to play a crucial role in disease prevention and patient health.

With the number of COVID-19 hospitalizations topping 19,000 the week of November 19 – 25, 2023, vigilance and preventative measures remain essential. The ACIP continues to recommend updated COVID vaccines for all patients aged 6 months and older, and your guidance can make a powerful difference.

To assist you, Moderna has assembled a concise resource that sheds light on the latest research and the importance of extended vigilance in combatting the spread of the SARS-CoV-2 virus.

The role of healthcare professionals is pivotal in guiding vaccine decisions. Studies show that messages involving a personal physician or a scientist recommending vaccination were the most compelling ways to improve vaccine adherence.

Together, we continue to strive to protect patients from COVID-19. Thank you for your relentless dedication and the difference you make every day.

For inquiries call 1-866-MODERNA (1-866-663-3762).

Pediatric COVID Vaccines Purchased on or After January 9, 2024 Now 100% Returnable

Important Announcement from Moderna:

Moderna is pleased to announce an important update to their vaccine return policy that they hope will have a positive impact on pediatric health and immunization rates.

Effective immediately, all privately purchased pediatric COVID-19 vaccine doses (NDC No. 80777-0287-92) purchased on or after January 9, 2024 will be 100% returnable for the entire season, pursuant to the return policies and procedures provided in your contract with Moderna.

This change is part of Moderna’s commitment to support healthcare providers and ensure that all children under the age of 12 have access to the COVID-19 vaccine.

Moderna understands the challenges faced by providers in predicting the exact number of doses needed. By allowing for increased returnability of unused pediatric COVID-19 vaccines, Moderna aims to eliminate the risk of unused excess supply for providers and encourage them to keep a healthy stock on-hand without the worry of excess inventory.

Let's work together to keep our children safe and healthy.

Upcoming Webinar: Protecting Kids from COVID-19

Many caregivers feel there’s no serious COVID-19 risk for their children, but hospitalizations and deaths persist in this age group, even without comorbidities.

Please join Moderna along with a panel of national experts on Tuesday, December 5, 2023 at 12:00 p.m. EST for a live, virtual event discussing COVID-19 and kids.

Topics will include:

  • The burden of pediatric COVID-19

  • Factors associated with severe outcomes

  • Past versus current vaccination uptake

  • Pediatric-specific risks and benefits

  • Common caregiver questions

In order to receive a webinar replay link, you must be registered for the event.

Pediatric COVID-19 Vaccinations: A Step-by-Step Guide from Moderna

Amid Modern’s ongoing efforts to safeguard children's health against COVID-19, they are reaching out to all customers to clarify the dosage and administration instructions for the COVID-19 Vaccine (2023-2024 Formula) authorized for ages 6 months through 11 years of age. Moderna‘s COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 11 years is supplied in single dose vials. A single dose for this age group is 0.25 mL. The single dose vials contain notably more than 0.25 mL of vaccine. Only a single 0.25 mL dose should be withdrawn from the vial. Discard the vial and excess volume after extracting a single dose.

To further support HCP education on our pediatric vials, please see the resources referenced below to all relevant constituents:

• “Dear HCP Letter” attached provides a thorough explanation of the dosing and administration guidance for our pediatric vials

• Training Video provides a step-by-step guide for accurately drawing and administering the pediatric COVID-19 vaccine from our vials, ensuring each child receives the proper dose.

Pfizer COVID-19 Vaccine NDC Notification

Updated COVID-19 vaccines from BioNTech and Pfizer are available. Here is a brief update on the market landscape:

  • Pfizer has substantial supply of 2023-2024 Formula COVID-19 vaccines and does not have any shortages at this time. 

  • Following FDA approval and emergency use authorization, the CDC issued recommendations the week of September 11, 2023.

  • Pfizer has shipped and delivered several million doses of 2023-2024 Formula COVID-19 vaccines. We continue to fulfill orders and anticipate delivering millions of additional doses each week.

  • Pfizer is actively working with our Wholesaler and Distributors partners and customers to help ensure access by shipping product directly to customers when and where needed.

Regarding reimbursement, there may be confusion related to reimbursement for COVID-19 vaccines and out of pocket costs to patients.  Under Section 3203 of the CARES Act and subsequent U.S. government guidance, most commercial health plans (excluding ACA grandfathered plans), must cover updated ACIP-recommended COVID-19 vaccines and their administration with no patient cost-sharing immediately upon approval or authorization for emergency use. As a result, commercial health plans must cover and reimburse claims for the updated Pfizer-BioNTech COVID-10 vaccines (2023-24 formula) as of the date of FDA approval and emergency use authorization on September 11, 2023.

In July 2023, HHS issued guidance to payors to prepare to cover COVID-19 vaccination with the onset of the COVID-19 vaccine Commercialization. To review this letter click on the attached link Letter from HHS Secretary on COVID-19 Vaccine Coverage | HHS.gov

 Click here to request a call from a Pfizer Vaccines Representative for information about updated COVID-19 vaccines from BioNTech and Pfizer or contact Tina Clark, your local Pfizer Vaccines Representative.

Vaccinate Against RSV this Respiratory Season

There are options to help prevent RSV and its potential serious consequences on infants and older adults this respiratory season.  ABRYSVOTM (Respiratory Syncytial Virus Vaccine) from Pfizer is the only FDA-approved and ACIP-recommended RSV vaccine to help protect both older adults and infants (via maternal immunization) from RSV.

RSV can lead to serious outcomes in older adults (annual data)

  • 2.2 million symptomatic illnesses

  • 60,000-160,000 hospitalizations

  • 6000-10,000 deaths

RSV is the leading cause of hospitalization in infants aged <1 year

  • Hospitalization burden is greatest in infants under 6 months of age, peaking between 1 and 2 months of age 3

  • In severe cases, RSV may result in acute respiratory failure, hypoxia and carbon dioxide retention, apnea, and death

 

Please review the Indications and Important Safety Information for ABRYSVO™ below.

 

ABRYSVO™ is ACIP recommended

  • The CDC’s ACIP recommends ABRYSVO™ for adults 60 years and older based on shared clinical decision making.6 The recommendation was published in the July 21, 2023, issue of MMWR, and is available here.

  • The CDC's ACIP recommends ABRYSVO for pregnant people as a one-time dose at 32 weeks and zero days’ through 36 weeks and 6 days’ gestation using seasonal administration (meaning September–January in most of the continental United States) for prevention of RSV-associated LRTI in infants aged <6 months.  The recommendation was published in the October 6, 2023, issue of MMWR, and is available here.

 

ABRYSVO™ is ACOG recommended

  • The American College of Obstetricians and Gynecologists (ACOG) recommends a single dose of maternal RSV vaccination for pregnant individuals 32 through 36 weeks gestation*, using seasonal administration, to prevent RSV lower respiratory tract infection in infants.

 

* Beginning on the first day of the 32nd week through the last day of the 36th week